Laurie H. Glimcher personifies the qualities honored by the George M. Kober Medal. A renowned immunologist who has taken on a series of leadership positions in medical education, research, and clinical care, she has played a key role in the rapidly advancing field of immunotherapy and in the lives and careers of scientists who are driving the field forward.

Dr. Glimcher (Figure 1), who became President and CEO of Dana-Farber Cancer Institute in Boston late last year, had an early exposure to the demands and rewards of a medical career; her father, Melvin Glimcher, was a prominent orthopedic surgeon at Massachusetts General Hospital and Boston Children’s Hospital. Over the course of a 40-year career, she has been, in many ways, a pioneer, not only as a scientist but as a model of professional achievement for women in science and academic medicine.

Laurie H. Glimcher, winner of the 2017 Association of American Physicians George M. Kober Medal. Image credit: Alexey Levchenko.

Dr. Glimcher graduated from Radcliffe College and earned her medical degree from Harvard Medical School in 1976, followed by internship and residencies at Mass. General and Brigham and Women’s Hospital. Her medical school studies sparked a fascination with the immune system and autoimmune disease. From 1979 to 1982, she conducted immunology research at the National Institutes of Health in the lab of the late William Paul, work that would later result in the discovery of the transcription factors XBP1 and T-bet, which play a role in immune system development and activation. It was during these early years that she also began raising a family.

Dr. Glimcher joined the Harvard T.H. Chan School of Public Health in 1984, and she was the Irene Heinz Given Professor of Immunology from 1991to 2011. As a professor of medicine at Harvard Medical School, she directed one of the world’s leading academic immunology programs.

Having devoted her career primarily to laboratory research, Dr. Glimcher decided to broaden her efforts. In 2012, she joined Weill Cornell Medical College as Dean and Professor of Medicine — becoming the first woman to serve as dean at the medical school — and Provost for Medical Affairs at Cornell University. There, she took steps to help women achieve work-life balance, setting up a daycare center and a grant program for postdoctoral fellows who are primary caregivers, and establishing an award program for excellence in mentoring women.

Her determination to do big things is captured in a comment she made after being named Dana-Farber’s President: “If you don’t aim high, you’re never going to make major discoveries.” As Dr. Glimcher has demonstrated, that passion can have as powerful an impact in the laboratory as in the culture of science and medicine itself.

Footnotes

Reference information: J Clin Invest. 2017;127(10):3575. https://doi.org/10.1172/JCI97404.

This article is adapted from a presentation at the 2017 AAP/ASCI/APSA Joint Meeting, April 22, 2017, in Chicago, Illinois, USA.

劳里·格里姆彻（Laurie H. Glimcher）代表了乔治·科伯（George M. Kober）勋章所授予的品质。她是著名的免疫学家，在医学教育，研究和临床护理中担任过一系列领导职务，在迅速发展的免疫疗法领域以及推动该领域前进的科学家的生活和职业中发挥了关键作用。

去年下半年成为波士顿达纳-法伯癌症研究所的总裁兼首席执行官的格利姆彻博士（图1）早日接触了医疗职业的要求和回报。她的父亲梅尔文·格利姆彻（Melvin Glimcher）是麻省总医院和波士顿儿童医院的著名骨科医生。在40年的职业生涯中，她在许多方面都是先驱，不仅是科学家，而且还是科学和学术医学领域女性职业成就的典范。

劳瑞·格利姆彻（Laurie H.Glimcher），2017年美国医师协会乔治·M·科伯（George M.Kober）奖章获得者。图片来源：Alexey Levchenko。

Glimcher博士毕业于拉德克利夫学院，并于1976年获得了哈佛医学院的医学学位，随后在马萨诸塞州综合医院，布里格姆妇女医院担任实习生和住院医师。她在医学院的研究激发了人们对免疫系统和自身免疫性疾病的迷恋。从1979年到1982年，她在已故威廉·保罗（William Paul）实验室中的美国国立卫生研究院（National Institutes of Health）进行了免疫学研究，这项工作后来导致发现转录因子XBP1和T-bet，它们在免疫系统的发育中起着重要作用。和激活。正是在这些早年，她也开始养家。

Glimcher博士于1984年加入哈佛大学Chan Chan公共卫生学院，并于1991年至2011年担任Irene Heinz免疫学教授。作为哈佛医学院的医学教授，她领导了世界领先的学术免疫学计划之一。

Glimcher博士主要致力于实验室研究，因此决定扩大自己的工作范围。2012年，她加入威尔·康奈尔医学院（Will Cornell Medical College）担任院长兼医学教授—成为第一位在医学院任院长的女性—并担任康奈尔大学医学事务教务长。她在那里采取措施，帮助妇女实现工作与生活的平衡，建立了日托中心，并为作为主要护理人员的博士后提供了补助金计划，并建立了奖励计划，以表彰杰出的女性指导。

她被任命为达纳·法伯（Dana-Farber）总裁后发表的评论中体现了她决心做大事的决心：“如果您的目标不高，就永远不会有重大发现。” 正如格里姆彻（Glimcher）博士所证明的那样，激情对实验室的影响与科学文化和医学文化一样强大。

脚注

参考信息：J Clin Invest。2017; 127（10）：3575。https://doi.org/10.1172/JCI97404。

本文改编自2017年4月22日在美国伊利诺伊州芝加哥举行的2017 AAP / ASCI / APSA联席会议上的演讲。